Vanguard Group
BCAX

Vanguard Group’s Bicara Therapeutics BCAX Stock Holding History

Vanguard Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$36.8M Sell
2,186,150
-14,775
-0.7% -$252K ﹤0.01% 2333
2025
Q3 		$34.8M Buy
2,200,925
+195,667
+10% +$2.19M ﹤0.01% 2333
2025
Q2 		$18.6M Buy
2,005,258
+914,140
+84% +$10.9M ﹤0.01% 2590
2025
Q1 		$14.2M Buy
1,091,118
+590
+0.1% +$7.83K ﹤0.01% 2660
2024
Q4 		$19M Buy
1,090,528
+1,020,528
+1,458% +$21.2M ﹤0.01% 2613
2024
Q3 		$1.78M Buy
+70,000
New +$1.79M ﹤0.01% 3595

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group's BCAX Position: Q4 2025 in Review

Vanguard Group reduced its Bicara Therapeutics (BCAX) stake by 0.67% in Q4 2025, selling an estimated $252K and leaving 2,186,150 shares worth $36.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2333.

Vanguard Group first reported a position in BCAX in Q3 2024 and has held it in 6 quarters since. 141 funds tracked by Wall St. Rank hold BCAX as of Q4 2025.

  • Vanguard Group held 2,186,150 shares of Bicara Therapeutics worth $36.8M as of Q4 2025.
  • Vanguard Group sold 14,775 Bicara Therapeutics shares in Q4 2025, an estimated $252K.
  • Bicara Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2333 holding.
  • Vanguard Group first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • 141 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.